Denali Therapeutics
DNLI
19.16
-0.12
-0.62%
Denali Therapeutics
US · DNLI
#2454 by market cap
Listed 2017
19.16
-0.12
-0.62%
Live - 5344 symbols - heartbeat 277s ago
· 2026-10-08 07:00
Pre-market
19.06
-0.52%
After-hours
19.16
0.00%
Overnight
19.16
0.00%
- Market cap
- 3.06B
- P/E (TTM)i
- -6.75
- P/Bi
- 3.67
- EPSi
- -2.97
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on DNLI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 10.75, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Margins
Key ratios & quality
- Altman Z-Scorei
- 10.75
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 129.16M | 26.68M | 335.66M | 48.66M | 108.46M | 330.53M | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 32.35M | 46.48M | 60.33M | 79.06M | 90.48M | 103.35M | 105.44M | 136.56M |
| Research & development | 143.18M | 193.38M | 212.62M | 265.35M | 358.73M | 423.88M | 396.44M | 418.78M |
| Operating profit | -46.37M | -213.18M | 62.72M | -295.75M | -340.74M | -196.70M | -501.88M | -555.34M |
| Pretax profit | -36.24M | -197.97M | 71.96M | -291.16M | -325.97M | -145.19M | -422.71M | -512.44M |
| Tax | 0 | -351.00K | 823.00K | -575.00K | 21.00K | 30.00K | 68.00K | 102.00K |
| Net profit | -36.24M | -197.61M | 71.14M | -290.58M | -325.99M | -145.22M | -422.77M | -512.54M |
| Basic EPS | 0 | -2 | 1 | -2 | -3 | -1 | -3 | -3 |
| Diluted EPS | -0.39 | -2.07 | 0.63 | -2.39 | -2.60 | -1.06 | -2.57 | -2.97 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | 0 | -- | -- | -- | 3.60M |
| Gross profit | -- | 0 | -- | -- | -- | 3.51M |
| Selling & admin expenses | 29.35M | 32.27M | 35.48M | 39.46M | 33.51M | 36.28M |
| Research & development | 116.23M | 102.70M | 101.95M | 97.91M | 103.85M | 97.02M |
| Operating profit | -145.58M | -134.96M | -137.43M | -137.37M | -137.36M | -130.54M |
| Pretax profit | -132.97M | -124.12M | -126.90M | -128.45M | -128.45M | -127.55M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -132.97M | -124.12M | -126.90M | -128.55M | -128.45M | -127.55M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.78 | -0.72 | -0.74 | -0.73 | -0.69 | -0.68 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 480.84M | 430.03M | 1.50B | 897.23M | 1.37B | 1.06B | 864.44M | 900.66M |
| Cash & ST investments | 464.30M | 415.36M | 1.47B | 865.41M | 1.34B | 1.03B | 832.33M | 867.88M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 661.98M | 553.23M | 1.60B | 1.40B | 1.46B | 1.15B | 1.37B | 1.14B |
| Total current liabilities | 32.79M | 45.34M | 71.70M | 378.25M | 363.92M | 77.98M | 102.21M | 98.35M |
| Short-term debt | -- | 3.67M | 4.69M | 5.45M | 7.32M | 7.26M | 12.03M | 9.55M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 115,139,000.00 | 158,341,000.00 | 453,749,000.00 | 441,871,000.00 | 417,812,000.00 | 122,963,000.00 | 144,496,000.00 | 131,093,000.00 |
| Total equity | 546.85M | 394.89M | 1.15B | 962.29M | 1.04B | 1.03B | 1.23B | 1.01B |
| Retained earnings | -227.94M | -425.55M | -354.42M | -645.00M | -970.99M | -1.12B | -1.54B | -2.05B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 878.64M | 934.71M | 882.60M | 900.66M | 1.02B | 753.93M |
| Cash & ST investments | 817.93M | 898.95M | 848.20M | 867.88M | 987.68M | 710.47M |
| Inventory | -- | -- | -- | -- | -- | 4.14M |
| Total assets | 1.27B | 1.17B | 1.06B | 1.14B | 1.27B | 1.16B |
| Total current liabilities | 91.88M | 91.06M | 90.15M | 98.35M | 110.16M | 90.08M |
| Short-term debt | 8.59M | 8.87M | 9.16M | 9.55M | 9.86M | 10.18M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 148,657,000.00 | 139,188,000.00 | 129,424,000.00 | 131,093,000.00 | 339,925,000.00 | 322,777,000.00 |
| Total equity | 1.12B | 1.03B | 926.20M | 1.01B | 926.10M | 835.18M |
| Retained earnings | -1.67B | -1.80B | -1.92B | -2.05B | -2.18B | -2.31B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 50.12M | -151.58M | 416.15M | -211.39M | -244.72M | -357.99M | -347.69M | -412.60M |
| Depreciation & amortization | 7.42M | 7.99M | 8.53M | 8.59M | 10.38M | 16.73M | 8.99M | 14.81M |
| Free cash flow | 46.72M | -169.50M | 413.06M | -219.89M | -262.55M | -370.93M | -363.61M | -422.10M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 94.41M | 0 | 614.09M | 0 | 296.22M | 0 | 499.25M | 189.25M |
| Ending cash balance | 78.62M | 80.95M | 508.64M | 294.98M | 219.54M | 128.68M | 176.54M | 208.43M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -131.47M | -75.30M | -107.30M | -98.54M | -131.20M | -97.00M |
| Depreciation & amortization | 3.21M | 3.96M | 3.86M | 3.78M | 3.76M | 4.48M |
| Free cash flow | -136.55M | -79.58M | -105.92M | -100.06M | -133.67M | -126.61M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 189.25M | -- | -- |
| Ending cash balance | 60.05M | 144.31M | 94.07M | 208.43M | 390.73M | 204.64M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -7.16 | -41.97 | 9.21 | -27.51 | -32.52 | -14.01 | -37.40 | -45.69 |
| ROA %i | -6.31 | -32.52 | 6.59 | -19.32 | -22.76 | -11.11 | -33.45 | -40.69 |
| ROIC %i | -7.16 | -36.37 | 8.43 | -26.29 | -31.72 | -17.01 | -41.28 | -47.70 |
| 5-year avg ROE %i | -- | -- | -- | -22.98 | -19.99 | -21.36 | -20.45 | -31.43 |
| EBIT margin %i | -35.90 | -799.10 | 18.69 | -607.78 | -314.16 | -59.51 | -- | -- |
| FCF / sales %i | 36.17 | -- | 123.06 | -- | -- | -- | -- | -- |
| Current ratioi | 14.67 | 9.48 | 20.86 | 2.37 | 3.77 | 13.65 | 8.46 | 9.16 |
| Quick ratioi | 14.16 | 9.16 | 20.58 | 2.29 | 3.70 | 13.31 | 8.16 | 8.85 |
| Debt / assetsi | 0.00 | 13.11 | 4.29 | 4.56 | 4.13 | 4.53 | 3.54 | 3.21 |
| LT debt / equityi | -- | 17.44 | 5.58 | 6.08 | 5.09 | 4.36 | 2.98 | 2.68 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -27.78 | 59.60 | -0.51 | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -35.21 | -39.69 | -44.44 | -45.69 | -49.59 | -54.93 |
| ROA %i | -31.83 | -35.90 | -39.75 | -40.69 | -40.04 | -44.01 |
| ROIC %i | -38.49 | -42.53 | -46.80 | -47.70 | -51.34 | -55.93 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -15,058.19 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 9.56 | 10.27 | 9.79 | 9.16 | 9.28 | 8.37 |
| Quick ratioi | 8.90 | 9.87 | 9.41 | 8.85 | 8.97 | 7.93 |
| Debt / assetsi | 3.83 | 3.99 | 4.21 | 3.21 | 2.73 | 2.78 |
| LT debt / equityi | 3.57 | 3.67 | 3.80 | 2.68 | 2.66 | 2.64 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Product revenue, net100.00%
Quote time 2026-10-08 07:00:03 · For reference only, not investment advice and not tailored to your situation.